28106239|t|Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma
28106239|a|To evaluate the therapeutic outcome of intravitreal melphalan injection in the management of vitreous disease in patients with retinoblastoma. We particularly aimed to assess whether higher melphalan dose with lower number of injections was more effective and associated with fewer side effects. This retrospective, interventional, noncomparative, and nonrandomized study included 39 eyes of 37 patients. Vitreous seeds were classified as dust, sphere, and cloud types. Intravitreal injections were performed through pars plana free of any visible tumor using 30-G needle. Response of the seeds (disappearance, conversion into inactive debris, or progression) and enucleation rate were determined as outcome measures. All patients previously received systemic or intra-arterial chemotherapy. Vitreous seeding was primary in 54% of eyes and secondary in 46% of eyes. Vitreous seeds were classified as dust in 9 (23.1%) eyes, sphere in 24 (61.5%) eyes, and cloud in 6 (15.4%) eyes. Melphalan dose varied between 20 and 40 µg and 20 (51.3%) eyes received >30 µg. The total number of injections was 70 (range 1-5, mean 1.8 per eye). Various types of regression were obtained in 27 (69.2%) eyes. Sphere-type seeds were the most responsive to melphalan. Nonresponse and disease progression were noted in 12 (30.8%) eyes. After a mean follow-up of 11.8 months, 17 (44%) eyes were enucleated. Vitreous hemorrhage (18%) and retinal pigment epithelial alterations (8%) were the most common side effects. Intravitreal melphalan at 30-40 µg in 1 or 2 injections proved effective in 69.2% of eyes with vitreous disease.
28106239	0	12	Intravitreal	T169	C1517572
28106239	13	25	chemotherapy	T061	C3665472
28106239	33	43	management	T058	C0376636
28106239	47	63	vitreous disease	T047	C0155365
28106239	67	81	retinoblastoma	T191	C0035335
28106239	98	117	therapeutic outcome	T080	C0085415
28106239	121	133	intravitreal	T169	C1517572
28106239	134	143	melphalan	T116,T121	C0025241
28106239	144	153	injection	T122	C1272883
28106239	161	171	management	T058	C0376636
28106239	175	191	vitreous disease	T047	C0155365
28106239	195	203	patients	T101	C0030705
28106239	209	223	retinoblastoma	T191	C0035335
28106239	265	271	higher	T080	C0205250
28106239	272	281	melphalan	T116,T121	C0025241
28106239	282	286	dose	T081	C0178602
28106239	292	297	lower	T080	C0205251
28106239	298	304	number	T081	C0237753
28106239	308	318	injections	T122	C1272883
28106239	328	337	effective	T080	C1704419
28106239	342	357	associated with	T080	C0332281
28106239	358	363	fewer	T081	C0205388
28106239	364	376	side effects	T046	C0879626
28106239	383	396	retrospective	T062	C0035363
28106239	398	412	interventional	T062	C3274035
28106239	414	428	noncomparative	T062	C2603343
28106239	434	453	nonrandomized study	T062	C2603343
28106239	466	470	eyes	T023	C0015392
28106239	477	485	patients	T101	C0030705
28106239	487	501	Vitreous seeds	T033	C1719830
28106239	507	517	classified	T185	C0008902
28106239	521	525	dust	T191	C0027651
28106239	527	533	sphere	T191	C0027651
28106239	539	550	cloud types	T191	C0027651
28106239	552	564	Intravitreal	T169	C1517572
28106239	565	575	injections	T122	C1272883
28106239	581	590	performed	T169	C0884358
28106239	591	598	through	T169	C0332273
28106239	599	609	pars plana	T023	C0229167
28106239	622	629	visible	T080	C0205379
28106239	630	635	tumor	T191	C0027651
28106239	636	641	using	T169	C1524063
28106239	642	653	30-G needle	T074	C0027551
28106239	655	676	Response of the seeds	T040	C1817727
28106239	678	691	disappearance	T033	C0243095
28106239	693	703	conversion	T169	C0439836
28106239	709	724	inactive debris	T033	C1720491
28106239	729	740	progression	T191	C0178874
28106239	746	757	enucleation	T061	C0014392
28106239	758	762	rate	T081	C1521828
28106239	782	789	outcome	T080	C0085415
28106239	790	798	measures	T081	C0079809
28106239	804	812	patients	T101	C0030705
28106239	824	832	received	T080	C1514756
28106239	833	841	systemic	T061	C1883256
28106239	845	872	intra-arterial chemotherapy	T061	C0842399
28106239	874	890	Vitreous seeding	T033	C1719830
28106239	895	902	primary	T080	C0205225
28106239	913	917	eyes	T023	C0015392
28106239	922	931	secondary	T080	C0175668
28106239	942	946	eyes	T023	C0015392
28106239	948	962	Vitreous seeds	T033	C1719830
28106239	968	978	classified	T185	C0008902
28106239	982	986	dust	T191	C0027651
28106239	1000	1004	eyes	T023	C0015392
28106239	1006	1012	sphere	T191	C0027651
28106239	1027	1031	eyes	T023	C0015392
28106239	1037	1042	cloud	T191	C0027651
28106239	1056	1060	eyes	T023	C0015392
28106239	1062	1071	Melphalan	T116,T121	C0025241
28106239	1072	1076	dose	T081	C0178602
28106239	1120	1124	eyes	T023	C0015392
28106239	1125	1133	received	T080	C1514756
28106239	1146	1158	total number	T081	C4288115
28106239	1162	1172	injections	T122	C1272883
28106239	1192	1196	mean	T081	C0444504
28106239	1205	1208	eye	T023	C0015392
28106239	1211	1218	Various	T081	C0439064
28106239	1219	1224	types	T080	C0332307
28106239	1228	1238	regression	T046	C0684320
28106239	1244	1252	obtained	T169	C1301820
28106239	1267	1271	eyes	T023	C0015392
28106239	1273	1290	Sphere-type seeds	T191	C0027651
28106239	1300	1304	most	T081	C0205393
28106239	1305	1315	responsive	T169	C0205342
28106239	1319	1328	melphalan	T116,T121	C0025241
28106239	1330	1341	Nonresponse	T033	C3844724
28106239	1346	1365	disease progression	T046	C0242656
28106239	1371	1376	noted	T080	C4288581
28106239	1391	1395	eyes	T023	C0015392
28106239	1405	1409	mean	T081	C0444504
28106239	1410	1419	follow-up	T058	C1522577
28106239	1428	1434	months	T079	C0439231
28106239	1445	1449	eyes	T023	C0015392
28106239	1455	1465	enucleated	T037	C1396718
28106239	1467	1486	Vitreous hemorrhage	T046	C0042909
28106239	1497	1523	retinal pigment epithelial	T023	C0035322
28106239	1524	1535	alterations	T078	C1515926
28106239	1550	1554	most	T081	C0205393
28106239	1555	1561	common	T081	C0205214
28106239	1562	1574	side effects	T046	C0879626
28106239	1576	1588	Intravitreal	T169	C1517572
28106239	1589	1598	melphalan	T116,T121	C0025241
28106239	1621	1631	injections	T122	C1272883
28106239	1639	1648	effective	T080	C1704419
28106239	1661	1665	eyes	T023	C0015392
28106239	1671	1687	vitreous disease	T047	C0155365